(Q37529990)

English

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

scientific article published on 23 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Gregory P Sfakianos

1

1 reference

Europe PubMed Central

20 August 2017

T Michael Numnum

2

1 reference

Europe PubMed Central

20 August 2017

Caitlin B Halverson

3

1 reference

Europe PubMed Central

20 August 2017

Deepa Panjeti

4

1 reference

Europe PubMed Central

20 August 2017

James E Kendrick

5

1 reference

Europe PubMed Central

20 August 2017

J Michael Straughn

6

1 reference

Europe PubMed Central

20 August 2017

language of work or name

0 references

publication date

23 June 2009

1 reference

Europe PubMed Central

20 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

20 August 2017

114

1 reference

Europe PubMed Central

20 August 2017

3

1 reference

Europe PubMed Central

20 August 2017

424-426

1 reference

Europe PubMed Central

20 August 2017

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Optimal sequencing in the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Recurrent ovarian cancer: how important is it to treat to disease progression?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

The role of bevacizumab in ovarian cancer--an evolving story

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.05.031

7 January 2021

Identifiers

10.1016/J.YGYNO.2009.05.031

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37529990&oldid=2127778058"